Syngene International, the Bengaluru-based contract research, development, and manufacturing organisation (CRDMO), has announced the extension of its collaboration with US-based biopharma firm, Bristol Myers Squibb (BMS) by another five years, to 2035.
The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry biology, drug metabolism and pharmacokinetics), translational services, pharmaceutical development & manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialisation, a Syngene press note informed.
On expanding the 25 year old collaboration, Peter Bains, MD and CEO of Syngene, said, it “enables us to plan together for the future in terms of building new capabilities and infrastructure with a decade long horizon. Taking a long-term perspective is a key feature of our partnership which adds strategic value to both companies.”
Ms. Payal Sheth, Senior Vice President, Therapeutic Discovery Sciences, BMS, noted that the long-standing partnership with Syngene, was instrumental in advancing BMS’s scientific ambitions.
Syngene and BMS’ collaboration started in 1998, culminating in the establishment of the Biocon Bristol Myers Squibb Research and Development Centre (BBRC) - Syngene’s first dedicated R&D centre. The centre was fully commissioned in 2009, the company said.
BBRC has since evolved into a major strategic R&D site for BMS, supporting integrated capabilities across target identification, lead discovery, lead optimisation, pharmaceutical development, molecular and cell biology, protein sciences, assay biology and clinical biomarkers, Syngene added.
The centre houses about 700 Syngene scientists working as an extension of BMS global research organisation, contributing to discovery, preclinical development, and patent filings across therapeutic areas including cardiovascular, fibrosis, immunology, and oncology, the note said.


20 January, 2026 16:58:53 IST 

















